Advancing access to affordable medicines
International Generic and Biosimilar Medicines Association (IGBA) (igbamedicines.org) scores 71 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Non-profit brands, in the 27th percentile of 18027 Healthcare brands.
The International Generic and Biosimilar Medicines Association (IGBA) is a global network that connects national and regional generic and biosimilar medicines associations. It advocates for policies that support access to affordable, high-quality generic and biosimilar drugs, serving as a unified voice for manufacturers, policymakers, and healthcare stakeholders worldwide. IGBA's work centers on international collaboration to influence regulatory and policy frameworks that affect the generic and biosimilar medicines industry, ultimately aiming to improve patient access to treatment globally.
| Brand Name | International Generic and Biosimilar Medicines Association (IGBA) |
|---|---|
| Domain | igbamedicines.org |
| Industry | Healthcare, Non-profit |
| Main Competitors | Association for Accessible Medicines (77/100), Medicines for Europe (73/100), Biosimilars Council (75/100), Indian Pharmaceutical Alliance (74/100), Generics and Biosimilars Initiative (GaBI) (72/100) |
Moz Domain Authority 33/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "IGBA is an international network of generic and biosimilar medicines associations, promoting access to affordable generic and biosimilar medicines" (Meta description: 19 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: Microdata (Schema.org). Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache.
Social footprint: verified profiles on YouTube, LinkedIn, X (Twitter), Facebook, Instagram; no detected presence on GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is International Generic and Biosimilar Medicines Association (IGBA)?", Claude could identify the brand as of October 2026. IGBA is the global trade association representing manufacturers of generic and biosimilar medicines, advocating for policies that support affordable access to medicines worldwide. Best known for Representing and advocating globally for the generic and biosimilar medicines industry.
When asked "Best brands similar to International Generic and Biosimilar Medicines Association (IGBA)?", Claude would recommend International Generic and Biosimilar Medicines Association (IGBA) as of October 2026. If someone asks about organizations representing generic and biosimilar drugmakers globally, IGBA is a key reference point alongside regional bodies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
International Generic and Biosimilar Medicines Association (IGBA)'s main competitors in Healthcare: Association for Accessible Medicines (77/100), Medicines for Europe (73/100), Biosimilars Council (75/100), Indian Pharmaceutical Alliance (74/100), Generics and Biosimilars Initiative (GaBI) (72/100).
Sources: Brand Analyzer scan
IGBA is an international network of national and regional generic and biosimilar medicines associations. It functions as a non-profit industry association that unites these groups to advocate collectively for policies supporting affordable, high-quality generic and biosimilar medicines on a global scale.
Sources: International Generic and Biosimilar Medicines Association (IGBA) official site
International Generic and Biosimilar Medicines Association (IGBA) has low AI-search visibility, scoring 15/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 23, recommendation 32). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: International Generic and Biosimilar Medicines Association (IGBA) official site
International Generic and Biosimilar Medicines Association (IGBA) scores 32/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: International Generic and Biosimilar Medicines Association (IGBA) official site
International Generic and Biosimilar Medicines Association (IGBA) can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: International Generic and Biosimilar Medicines Association (IGBA) official site
IGBA does not sell physical products; instead, it offers advocacy, policy coordination, and collaborative networking services for its member associations. These services focus on promoting favorable regulatory environments and supporting global access to generic and biosimilar medicines.
Sources: International Generic and Biosimilar Medicines Association (IGBA) official site
IGBA's network includes national and regional generic and biosimilar medicines associations, pharmaceutical manufacturers, policymakers, and healthcare stakeholders. These groups engage with IGBA to coordinate advocacy efforts and influence policies affecting affordable medicine access worldwide.
Sources: International Generic and Biosimilar Medicines Association (IGBA) official site
International Generic and Biosimilar Medicines Association (IGBA) scores 15/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
International Generic and Biosimilar Medicines Association (IGBA) has a weak AI-visibility profile at 15/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (32/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 33/100. In a live check, Claude could already identify International Generic and Biosimilar Medicines Association (IGBA) from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to International Generic and Biosimilar Medicines Association (IGBA): IBS - Institut de Biologie Structurale (71/100), EPIC (European Prospective Investigation into Cancer and Nutrition) (71/100), IGPP - Institut für Grenzgebiete der Psychologie und Psychohygiene (71/100), iGrow (71/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.